LSI Segment Divestment

Cell & Gene Therapy (CGT) Market Continued strong market growth, with focus on regenerative treatments for COVID-19 Some non-COVID-19 therapies have been deprioritized Rapid pipeline expansion in 2020: >2,000 active therapies in development >1,100 regenerative medicine clinical trials Five landmark commercial approvals in the last two years Cost of production remains a challenge Lonza Operations Business continuity maintained through pandemic, agreement with new customer Altimmune allows for the supply of AdCOVID, a single-dose intranasal vaccine for COVID-19 Strong demand for our products and services New customer agreements have enabled differentiated service offerings in emerging modalities (e.g. partnership with BeTheMatch for apheresis networks management and cellular source material) Vein-to-vein supply chain network has been expanded to support CGT customers needs beyond manufacturing Financial Performance¹ Strong sales growth above the market, supported by solid demand from new and existing clients Margin and operational improvement through increased throughput on existing assets 2021 margin improvement anticipated through efficiency improvements and higher asset utilization 1 Comparison versus 2019 at a constant exchange rate (CER) 25

View entire presentation